Saab expects organic sales growth of between 12% and 16% in 2025, the Swedish defence equipment maker said on Friday, as it also updated its medium-term targets for 2023-2027.

International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the expansion in its software business.

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales